D-0126-2025 Class II Ongoing
FDA drug recall D-0126-2025 was initiated by Viatris Inc on Nov 18, 2024 and is designated Class II. Reason for recall: Superpotent Drug and Subpotent Drug: potency failures obtained The recall status is ongoing. Affected quantity: 43,765 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 18, 2024
- Initiation Date
- Nov 18, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 43,765 bottles
Product description
Levothyroxine Sodium Tablets USP, 88 mcg, packaged in a) 90-count bottles (NDC 0378-1807-77) and b) 1000-count bottles (NDC 0378-1807-10), Rx only, Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A.
Reason for recall
Superpotent Drug and Subpotent Drug: potency failures obtained
Distribution pattern
Nationwide within the United States and Puerto Rico
Code information
Lot # a) 8180781, Exp. Date Aug 2025; b)3191628, Exp. Date Feb 2025; 3197139, Exp. Date Apr 2025; 3188976, Exp. Date Jan 2025; 3184929, Exp. Date Dec 2024; 3204909, Exp. Date Aug 2025
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0126-2025
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026